CA2865675C - Reprogramming effector protein interactions to correct epigenetic defects in cancer - Google Patents

Reprogramming effector protein interactions to correct epigenetic defects in cancer Download PDF

Info

Publication number
CA2865675C
CA2865675C CA2865675A CA2865675A CA2865675C CA 2865675 C CA2865675 C CA 2865675C CA 2865675 A CA2865675 A CA 2865675A CA 2865675 A CA2865675 A CA 2865675A CA 2865675 C CA2865675 C CA 2865675C
Authority
CA
Canada
Prior art keywords
mark
histone
compound
compounds
cognate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2865675A
Other languages
English (en)
French (fr)
Other versions
CA2865675A1 (en
Inventor
Steven J.M. JONES
Oleksandr YAKOVENKO
Silvia THOENE
Pierre Yulmin CHEUNG
Jianghong An
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Columbia Cancer Agency BCCA
Original Assignee
British Columbia Cancer Agency BCCA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Columbia Cancer Agency BCCA filed Critical British Columbia Cancer Agency BCCA
Publication of CA2865675A1 publication Critical patent/CA2865675A1/en
Application granted granted Critical
Publication of CA2865675C publication Critical patent/CA2865675C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Computing Systems (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Library & Information Science (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2865675A 2012-02-27 2013-02-27 Reprogramming effector protein interactions to correct epigenetic defects in cancer Active CA2865675C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261603650P 2012-02-27 2012-02-27
US61/603,650 2012-02-27
US201261637282P 2012-04-24 2012-04-24
US61/637,282 2012-04-24
PCT/CA2013/050145 WO2013127011A1 (en) 2012-02-27 2013-02-27 Reprogramming effector protein interactions to correct epigenetic defects in cancer

Publications (2)

Publication Number Publication Date
CA2865675A1 CA2865675A1 (en) 2013-09-06
CA2865675C true CA2865675C (en) 2023-02-28

Family

ID=49081499

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2865675A Active CA2865675C (en) 2012-02-27 2013-02-27 Reprogramming effector protein interactions to correct epigenetic defects in cancer

Country Status (11)

Country Link
US (1) US9552457B2 (env)
EP (1) EP2819662B1 (env)
JP (1) JP6137703B2 (env)
KR (1) KR102149860B1 (env)
CN (1) CN104136020B (env)
AU (1) AU2013225592B2 (env)
BR (1) BR112014021201B1 (env)
CA (1) CA2865675C (env)
IN (1) IN2014DN07812A (env)
RU (1) RU2637441C2 (env)
WO (1) WO2013127011A1 (env)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2907184C (en) * 2013-03-15 2022-12-06 Sutter West Bay Hospitals Falz for use as a target for therapies to treat cancer
WO2015033228A2 (en) * 2013-09-09 2015-03-12 Glionova Ab Compounds and use for treating cancer
EP3064205A1 (en) * 2015-03-06 2016-09-07 Glionova AB Therapeutic use of isomeric forms of 2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol
US20180223368A1 (en) * 2015-03-18 2018-08-09 Memorial Sloan Ketteting Cancer Center Methods for diagnosing and treating follicular lymphoma
EP4571274A3 (en) 2015-07-31 2025-08-20 Sanofi-Aventis Deutschland GmbH Sensor, cartridge and drug delivery device
CN111885914B (zh) * 2017-10-27 2022-05-13 投资健康有限责任公司 使用芴衍生物制造扩增的造血干细胞的组合物和方法
WO2022081892A1 (en) * 2020-10-14 2022-04-21 The Regents Of The University Of California Systems for and methods of determining protein-protein interaction

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE603039A (env) * 1960-04-26
GB1120461A (en) 1964-07-06 1968-07-17 Manuf Prod Pharma Derivatives of fluoreno-[1,9-ef]1,4-diazepine-1-oxide
US3622580A (en) * 1969-03-25 1971-11-23 Smith Kline French Lab Piperazino-acetylamino-9-fluorenones and-anthraquinones
LU85246A1 (fr) * 1984-03-13 1985-10-14 R L Galephar Sa 2-(aminoalkyl)acrylophenones,leur preparation et leur utilisation
US5501959A (en) 1989-01-17 1996-03-26 Alamar Biosciences Laboratory, Inc. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents
JP2002523057A (ja) * 1998-08-25 2002-07-30 ザ スクリップス リサーチ インスティテュート タンパク質の機能を予測するための方法およびシステム
US7928218B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
AU2007254179B2 (en) * 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
WO2009015283A2 (en) * 2007-07-24 2009-01-29 President And Fellows Of Harvard College Bhc80 - histone complexes and uses thereof
CN104557914A (zh) 2008-09-26 2015-04-29 新加坡科技研究局 3-脱氮瓶菌素衍生物
WO2010045199A2 (en) * 2008-10-13 2010-04-22 University Of South Florida Method of modulating ship activity
GB0822248D0 (en) 2008-12-05 2009-01-14 Medical Res Council Crystal meths
WO2010094009A2 (en) * 2009-02-13 2010-08-19 Children's Hospital Medical Center Methods and compositions for the treatment of ras associated disorders
CA2769038A1 (en) * 2009-07-31 2011-02-03 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Antiangiogenic small molecules and methods of use
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
MX384074B (es) 2010-05-14 2025-03-12 Dana Farber Cancer Inst Inc Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012071469A2 (en) 2010-11-23 2012-05-31 Nevada Cancer Institute Histone demethylase inhibitors and uses thereof for treatment o f cancer
CA2828212A1 (en) 2011-02-23 2012-08-30 Shiraz Mujtaba Inhibitors of bromodomains as modulators of gene expression
WO2012123119A1 (en) 2011-03-17 2012-09-20 Cellzome Ag Methods for the identification and characterization of proteins interacting with histone tails and of compounds interacting with said proteins
WO2013059944A1 (en) 2011-10-28 2013-05-02 British Columbia Cancer Agency Branch Epigenetic regulators and uses thereof

Also Published As

Publication number Publication date
CA2865675A1 (en) 2013-09-06
JP6137703B2 (ja) 2017-05-31
EP2819662A1 (en) 2015-01-07
IN2014DN07812A (env) 2015-05-15
RU2014138543A (ru) 2016-04-20
BR112014021201B1 (pt) 2023-01-24
KR102149860B1 (ko) 2020-08-31
EP2819662A4 (en) 2016-03-23
CN104136020B (zh) 2018-08-28
RU2637441C2 (ru) 2017-12-04
AU2013225592A2 (en) 2014-10-09
US20150154345A1 (en) 2015-06-04
CN104136020A (zh) 2014-11-05
KR20140132382A (ko) 2014-11-17
AU2013225592A1 (en) 2014-10-09
BR112014021201A2 (pt) 2021-06-08
WO2013127011A1 (en) 2013-09-06
US9552457B2 (en) 2017-01-24
JP2015515448A (ja) 2015-05-28
EP2819662B1 (en) 2019-04-10
AU2013225592B2 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
EP2819662B1 (en) Reprogramming effector protein interactions to correct epigenetic defects in cancer
JP6122006B2 (ja) ヒストン脱メチル化酵素阻害剤としての、置換された（ｅ）−ｎ’−（１−フェニルエチリデン）ベンゾヒドラジド類似体
EP3010915B1 (en) Substituted (3-(5-chloro-2-hydroxyphenyl)-1-benzoyl-1h-pyrazole compounds as histone demethylase inhibitors
TW201728583A (zh) 氨基噻唑化合物及其用途
US20230381180A1 (en) Small molecule modulators of ksr-bound mek
EP2134703A1 (en) Amide derivatives as calcium channel blockers
Deng et al. Identification of small molecule sphingomyelin synthase inhibitors
WO2013059944A1 (en) Epigenetic regulators and uses thereof
EP3148967B1 (en) Sulfonamide compounds and their use as stat5 inhibitors
US20250263404A1 (en) Aminopyridines as activators of pi3 kinase
US20090137681A1 (en) Sirtuin Inhibiting Compounds
Marín‐Ramos et al. Development of a nucleotide exchange inhibitor that impairs Ras oncogenic signaling
WO2020210662A1 (en) Small molecules for cancer therapy that reduce the expression of transcription factors klf5 and egr-1
KR102285119B1 (ko) 신규한 히스톤 메틸 트랜스퍼라아제 억제제 및 그 용도
US10689381B2 (en) Vinblastine 20″ amides: synthetic analogs that maintain or improve potency and simultaneously overcome Pgp-derived efflux and resistance
Pinheiro et al. Microwave-assisted single-step synthesis of cyclic and acyclic β-aminosulfones and evaluation of their antifungal activity targeting CYP51
Depetter Synthesis of selective HDAC6 inhibitors and their evaluation in cancer models
US20220306603A1 (en) Targeting dna repair in tumor cells via inhibition of ercc1-xpf
CA2963422A1 (en) Poly(adp-ribose) polymerase 1 inhibitors structurally unrelated to nad
NZ621078B2 (en) Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180223